Consumer Watchdog

Expose. Confront. Change.

Consumer Watchdog

Privacy

Consumer Watchdog investigations and advocacy on data privacy, surveillance, AI, and your right to control your personal information.
Debate rages over UW stem-cell patents

Debate rages over UW stem-cell patents

<p class="source">Wisconsin State Journal</p> <p>The government's review of the three patents started last year at the request of two groups: the Foundation for Taxpayer and Consumer Rights in Santa Monica, Calif., which is involved in California's $3 billion stem-cell initiative; and the New York-based Public Patent Foundation. John Simpson, stem-cell director for the California group, said WARF's licensing fees, of up to $400,000, impede stem-cell research. He called WARF's response to the patent office rejection a "rehash of old arguments."</p>
WARF questions relevancy of documents used to uphold patent challenge

WARF questions relevancy of documents used to uphold patent challenge

<p class="source">Wisconsin Technology Network</p> <p>The patent challenge was pursued in part because the Foundation for Taxpayer and Consumer Rights, citing the complaints of scientists, felt the stem cell patents were restricting research. John Simpson, stem cell project director for the FTCR, said WARF acknowledged as much earlier this year when it announced it was easing its stem cell licensing restrictions.</p>
Wis. foundation challenges decision to reject stem cell patents

Wis. foundation challenges decision to reject stem cell patents

<p class="source">Associated Press </p> <p>The California-based Foundation for Taxpayer and Consumer Rights and others are challenging patents that cover discoveries by Thomson, who was the first to grow and isolate human embryonic stem cells in 1998. In a preliminary decision released in April, the U.S. Patent and Trademark Office said it was preparing to throw out the patents because Thomson's discoveries were obvious given previous research by other scientists.</p>
Coupon-Based Settlements Get Tougher;

Coupon-Based Settlements Get Tougher;

<h3>Under New Laws, Trial Judges Get More Discretion</h3><p class="source">Los Angeles Daily Journal</p> <p>"In this situation, you have to buy more coverage or get a bigger deductible or add someone to your policy, which all costs more than the amount of money you're supposed to get back," said Harvey Rosenfield, an attorney with the Foundation for Taxpayer and Consumer Rights, which objected to the settlements. "That's like a thief saying, 'I'll give the 50 bucks I stole, but I insist that you give me 60 bucks first.'"</p>
Stem cell institute bonds can be issued;

Stem cell institute bonds can be issued;

<h3>State high court declines to review previous ruling</h3><p class="source">The San Diego Union-Tribune</p> <p>Taxpayer advocates, who monitored and critiqued the institute for the past two years as its standards and policies were formulated in public meetings, lauded the court's decision, but remained cautions. "Like anyone else interested in stem cell science, I am delighted with the court's decision," said John Simpson, of the Foundation for Consumer and Taxpayer Rights in Santa Monica. "But I hope in light of the understandable exuberance that everyone at the institute must be feeling that they don't forget the very solid procedures that they have put in place... and hand money willy nilly out the door."</p>
At WellPoint, Glasscock is reducing role and holdings

At WellPoint, Glasscock is reducing role and holdings

<p class="source">The Indianapolis Star (Indiana)</p> <p>The millions paid out to top executives at WellPoint and other health insurers have drawn sharp criticism at a time when the affordability of health care remains one of the nation's most pressing issues. "It's feast for the executives and famine for the patients at WellPoint," said Jamie Court, president of the Foundation for Taxpayer and Consumer Rights, a California-based advocacy group that has been a frequent critic of WellPoint.</p>
THE MARKET’S THE PROBLEM WITH HEALTH CARE

THE MARKET’S THE PROBLEM WITH HEALTH CARE

<p class="source">Marketplace Radio Program (American Public Media)</p> <p>There are two things you can mention to almost any CEO in this country that will provoke an immediate response, one is global warming and how to balance protecting the environment with protecting the economy. The other is health care and how companies can protect their bottom lines. Safeway CEO Steve Burd launched a health care reform effort this week. Burd and three-dozen other Fortune 500 CEOs are calling for a market solution. Commentator and consumer advocate Jamie Court says that's great, but the market is the problem.</p>
THE MARKET’S THE PROBLEM WITH HEALTH CARE

THE MARKET’S THE PROBLEM WITH HEALTH CARE

<p class="source">Marketplace Radio Program (American Public Media)</p> <p>There are two things you can mention to almost any CEO in this country that will provoke an immediate response, one is global warming and how to balance protecting the environment with protecting the economy. The other is health care and how companies can protect their bottom lines. Safeway CEO Steve Burd launched a health care reform effort this week. Burd and three-dozen other Fortune 500 CEOs are calling for a market solution. Commentator and consumer advocate Jamie Court says that's great, but the market is the problem.</p>
Schwarzenegger’s fundraising questioned;

Schwarzenegger’s fundraising questioned;

<h3>TERMED-OUT SCHWARZENEGGER STILL RAKING IT IN, CRITICS SAY</h3><p class="source">San Jose Mercury News, (California)</p> <p>Frequent Schwarzenegger critic Jamie Court, of the Foundation for Taxpayer and Consumer Rights, describes it as a "no-limits, hold 'em slush fund. He is a termed-out politician and shouldn't be raising a dime unless he has a ballot initiative," Court said. "And then, he should be raising contributions with a limited value." That last comment alludes to the fact that Schwarzenegger's legal team helped eliminate contribution limits for campaign committees such as the California Recovery Team.</p>
Supreme Court ruling seen as blow to WARF stem cell patents

Supreme Court ruling seen as blow to WARF stem cell patents

<p class="source">Wisconsin Technology Network</p> <p>"The consensus generally was that the federal circuit court had swung too far in the direction of patent holders," said John Simpson, stem cell project director for the FTCR. "The decision is part of a trend in the Supreme Court to swing back the other way. Obviousness will now be easier to prove."</p>
Ruling could aid challenge to UW stem cell patents;

Ruling could aid challenge to UW stem cell patents;

<h3>Supreme Court affirms basis of patent objection</h3><p class="source">Milwaukee Sentinel-Journal (Wisconsin)</p> <p>"We thought what James Thomson did was obvious when we filed the challenges, so this would, if anything, enhance our case," said John M. Simpson, stem cell project director at the Foundation for Taxpayer and Consumer Rights, a consumer watchdog group in Santa Monica, Calif. The other group that in July requested the re-examination of WARF's patents is the Public Patent Foundation, a New York group that targets the patent system.</p>
Group calls for WARF director’s resignation from Patent Office board

Group calls for WARF director’s resignation from Patent Office board

<p class="source">Milwaukee Business Journal</p> <p>The Foundation for Taxpayer and Consumer Rights and the Public Patent Foundation, of New York, challenged the WARF patents in July 2006. The two groups said they brought the challenge because the three WARF patents were impeding scientific progress and driving vital stem cell research overseas, where the patents are not recognized.</p>